FSME-IMMUN/TicoVac — Revenues:
Pfizer FSME-IMMUN/TicoVac — Revenues: increased by 72.3% to $81.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.6%, from $63.00M to $81.00M. Over 4 years (FY 2021 to FY 2025), FSME-IMMUN/TicoVac — Revenues: shows an upward trend with a 14.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration or higher demand for tick-borne disease prevention, while a decrease may signal increased competition or seasonal fluctuations in vaccination rates.
Detailed definition
This metric represents the total gross sales generated from the specific vaccine product line focused on tick-borne ence...
Peer comparison
Comparable to specialized vaccine or prophylactic product revenue lines reported by other global pharmaceutical companies, often evaluated based on market share in endemic regions.
pfe_segment_fsme_immun_ticovac_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $61.00M | $47.00M | $24.00M | $42.00M | $68.00M | $67.00M | $23.00M | $45.00M | $101.00M | $91.00M | $31.00M | $65.00M | $100.00M | $81.00M | $34.00M | $63.00M | $109.00M | $100.00M | $47.00M | $81.00M |
| QoQ Change | — | -23.0% | -48.9% | +75.0% | +61.9% | -1.5% | -65.7% | +95.7% | +124.4% | -9.9% | -65.9% | +109.7% | +53.8% | -19.0% | -58.0% | +85.3% | +73.0% | -8.3% | -53.0% | +72.3% |
| YoY Change | — | — | — | — | +11.5% | +42.6% | -4.2% | +7.1% | +48.5% | +35.8% | +34.8% | +44.4% | -1.0% | -11.0% | +9.7% | -3.1% | +9.0% | +23.5% | +38.2% | +28.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's fsme-immun/ticovac — revenues:?
- Pfizer (PFE) reported fsme-immun/ticovac — revenues: of $81.00M in Q1 2026.
- How has Pfizer's fsme-immun/ticovac — revenues: changed year-over-year?
- Pfizer's fsme-immun/ticovac — revenues: increased by 28.6% year-over-year, from $63.00M to $81.00M.
- What is the long-term trend for Pfizer's fsme-immun/ticovac — revenues:?
- Over 4 years (2021 to 2025), Pfizer's fsme-immun/ticovac — revenues: has grown at a 14.6% compound annual growth rate (CAGR), from $185.00M to $319.00M.
- What does fsme-immun/ticovac — revenues: mean?
- The total revenue generated from the sale of tick-borne encephalitis vaccines.